Connect with us


FDA approves Roche’s new spinal muscular atrophy drug – MarketWatch



post featured image

Roche Holding AG
said Friday that the Food and Drug Administration had approved Evrysdi, a treatment for spinal muscular atrophy in adults and most children. It’s the second drug to be approved by the regulator to treat the rare disease. The therapy was developed by PTC Therapeutics Inc.
and will be marketed by Genentech, a division of Roche. “We believe Evrysdi, with its favorable clinical profile and oral administration, may offer meaningful benefits for ma…

Click here to view the original article.